Skip to main content
Top
Published in: Diabetologia 10/2004

01-10-2004 | Article

In vivo proliferation of differentiated pancreatic islet beta cells in transgenic mice expressing mutated cyclin-dependent kinase 4

Authors: S. Hino, T. Yamaoka, Y. Yamashita, T. Yamada, J. Hata, M. Itakura

Published in: Diabetologia | Issue 10/2004

Login to get access

Abstract

Aims/hypothesis

It has previously been hypothesised that highly differentiated endocrine cells do not proliferate or regenerate. However, recent studies have revealed that cyclin-dependent kinase 4 (CDK4) is necessary for the proliferation of pancreatic islet beta cells. The aim of this study was to determine whether activation of CDK4 can potentially be used as a radical treatment for diabetes without malignant transformation.

Methods

We generated transgenic mice expressing mutant CDK4 under the control of the insulin promoter to examine the effect of activated CDK4 overexpression in the postnatal development of pancreatic islets.

Results

In the transgenic mice, total CDK4 protein expression was increased by up to 5-fold, with a concomitant increase in CDK4 activity indicated by the detection of phosphorylated Rb protein in pancreatic islets. Histopathologically, many cells tested positive for proliferating cell nuclear antigen, and pancreatic islets displayed hyperplasia due to the extreme proliferation of beta cells containing a large number of insulin granules. Pancreatic islet alpha, delta and PP cells did not increase. Over an 18-month observation period, the transgenic mice did not develop insulinoma. Levels of expression of GLUT1 and c-myc were comparable to those in the littermates of the transgenic mice. GLUT2 expression was identified in the pancreatic islets of transgenic mice. No significant differences in telomerase activities were detected between transgenic mice and their littermates. Transgenic mice were superior to their littermates in terms of glucose tolerance and insulin secretion in response to the intraperitoneal injection of glucose, and hypoglycaemia was not observed.

Conclusions/interpretation

Activated CDK4 stimulates postnatal pancreatic beta cell proliferation, during which the highly differentiated phenotypes of pancreatic islet beta cells are preserved without malignant transformation.
Literature
2.
go back to reference Kitagawa M, Higashi H, Jung HK et al. (1996) The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 15:7060–7069PubMed Kitagawa M, Higashi H, Jung HK et al. (1996) The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 15:7060–7069PubMed
3.
go back to reference Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512PubMed Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512PubMed
4.
go back to reference Yamaoka T, Itakura M (1999) Development of pancreatic islets. Int J Mol Med 3:247–261PubMed Yamaoka T, Itakura M (1999) Development of pancreatic islets. Int J Mol Med 3:247–261PubMed
5.
go back to reference Tsutsui T, Hesabi B, Moons DS et al. (1999) Targeted disruption of CDK4 delays cell entry with enhanced p27Kip1 activity. Mol Cell Biol 10:7011–7019 Tsutsui T, Hesabi B, Moons DS et al. (1999) Targeted disruption of CDK4 delays cell entry with enhanced p27Kip1 activity. Mol Cell Biol 10:7011–7019
6.
go back to reference Rane SG, Dubus P, Mettus RV et al. (1999) Loss of CDK4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 22:44–52CrossRefPubMed Rane SG, Dubus P, Mettus RV et al. (1999) Loss of CDK4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 22:44–52CrossRefPubMed
7.
go back to reference Martin J, Hunt SL, Dudus P et al. (2003) Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene 22:5261–5269CrossRefPubMed Martin J, Hunt SL, Dudus P et al. (2003) Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene 22:5261–5269CrossRefPubMed
8.
go back to reference Sotillo R, Dubus P, Martin J et al. (2001) Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J 20:6637–6647CrossRefPubMed Sotillo R, Dubus P, Martin J et al. (2001) Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J 20:6637–6647CrossRefPubMed
9.
go back to reference Wolfel T, Hauer M, Schneider J et al. (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284PubMed Wolfel T, Hauer M, Schneider J et al. (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284PubMed
10.
go back to reference Zou L, Weger J, Yang Q et al. (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97–99CrossRefPubMed Zou L, Weger J, Yang Q et al. (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97–99CrossRefPubMed
11.
go back to reference Yamaoka T, Idehara C, Yano M et al. (1998) Hypoplasia of pancreatic islets in transgenic mice expressing activin receptor mutants. J Clin Invest 102:294–301PubMed Yamaoka T, Idehara C, Yano M et al. (1998) Hypoplasia of pancreatic islets in transgenic mice expressing activin receptor mutants. J Clin Invest 102:294–301PubMed
12.
go back to reference Hogan B, Beddington R, Costantini F, Lacy E (1994) Manipulating the mouse embryo. A laboratory manual, 2nd edition. Cold Spring Harbor Laboratory Press, New York Hogan B, Beddington R, Costantini F, Lacy E (1994) Manipulating the mouse embryo. A laboratory manual, 2nd edition. Cold Spring Harbor Laboratory Press, New York
13.
go back to reference Moritani M, Yoshimoto K, Ii S et al. (1996) Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. J Clin Invest 98:1851–1859PubMed Moritani M, Yoshimoto K, Ii S et al. (1996) Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. J Clin Invest 98:1851–1859PubMed
14.
go back to reference Gotoh M, Maki T, Kiyoizumi T, Satomo S, Monaco AP (1985) An improved method for isolation of mouse pancreatic islets. Transplantation 40:437–438PubMed Gotoh M, Maki T, Kiyoizumi T, Satomo S, Monaco AP (1985) An improved method for isolation of mouse pancreatic islets. Transplantation 40:437–438PubMed
15.
go back to reference Kato A, Takahashi H, Takahashi Y, Matsushime H (1997) Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition. J Biol Chem 272:8065–8070CrossRefPubMed Kato A, Takahashi H, Takahashi Y, Matsushime H (1997) Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition. J Biol Chem 272:8065–8070CrossRefPubMed
16.
go back to reference Matsushime H, Ewen ME, Strom DK et al. (1992) Identification and properties of an atypical catalytic subunit (p34PSK−J3/cdk4) for mammalian D type G1 cyclins. Cell 71:323–334CrossRefPubMed Matsushime H, Ewen ME, Strom DK et al. (1992) Identification and properties of an atypical catalytic subunit (p34PSK−J3/cdk4) for mammalian D type G1 cyclins. Cell 71:323–334CrossRefPubMed
17.
go back to reference Yamada T, Brunstedt J, Solomon T (1983) Chronic effects of caerulein and secretion on endocrine of the rat. Am J Physiol 24:G541–G545 Yamada T, Brunstedt J, Solomon T (1983) Chronic effects of caerulein and secretion on endocrine of the rat. Am J Physiol 24:G541–G545
18.
go back to reference Kim NW, Piatyszek MA, Prowse KR et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015PubMed Kim NW, Piatyszek MA, Prowse KR et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015PubMed
19.
go back to reference Asplund K (1973) Dynamics of insulin release from the fetal and neonatal rat pancreas. Eur J Clin Invest 3:338–344PubMed Asplund K (1973) Dynamics of insulin release from the fetal and neonatal rat pancreas. Eur J Clin Invest 3:338–344PubMed
20.
go back to reference Hole RL, Pian-Smith MC, Sharp GW (1988) Development of the biphasic response to glucose in fetal and neonatal rat pancreas. Am J Physiol 254:E167–E174PubMed Hole RL, Pian-Smith MC, Sharp GW (1988) Development of the biphasic response to glucose in fetal and neonatal rat pancreas. Am J Physiol 254:E167–E174PubMed
21.
go back to reference Otonkoski T, Anderson S, Knip M, Simell O (1988) Maturation of insulin response to glucose during human fetal and neonatal development. Diabetes 37:286–291PubMed Otonkoski T, Anderson S, Knip M, Simell O (1988) Maturation of insulin response to glucose during human fetal and neonatal development. Diabetes 37:286–291PubMed
22.
go back to reference Weinhaus AF, Poronnik P, Cook DI, Tuch BE (1995) Insulin secretagogues, but not glucose, stimulate an increase in [Ca++] in the fetal rat beta cell. Diabetes 44:118–124PubMed Weinhaus AF, Poronnik P, Cook DI, Tuch BE (1995) Insulin secretagogues, but not glucose, stimulate an increase in [Ca++] in the fetal rat beta cell. Diabetes 44:118–124PubMed
23.
go back to reference Boden G, Murer E, Mozzoli M (1994) Glucose transporter proteins in human insulinoma. Ann Intern Med 121:109–112PubMed Boden G, Murer E, Mozzoli M (1994) Glucose transporter proteins in human insulinoma. Ann Intern Med 121:109–112PubMed
24.
go back to reference Miyamoto T, Kakizawa T, Ichikawa K, Nishio, S, Kajikawa S, Hashizume K (2001) Expression of dominant negative form of PAX4 in human insulinoma. Biochem Biophys Res Commun 282:34–40CrossRefPubMed Miyamoto T, Kakizawa T, Ichikawa K, Nishio, S, Kajikawa S, Hashizume K (2001) Expression of dominant negative form of PAX4 in human insulinoma. Biochem Biophys Res Commun 282:34–40CrossRefPubMed
25.
go back to reference Pavelic K, Hrascan R, Kapitanovic S et al. (1995) Multiple genetic alterations in malignant metastatic insulinomas. J Pathol 177:395–400PubMed Pavelic K, Hrascan R, Kapitanovic S et al. (1995) Multiple genetic alterations in malignant metastatic insulinomas. J Pathol 177:395–400PubMed
26.
go back to reference Pavelic K, Hrascan R, Kapitanovic S et al. (1996) Molecular genetics of malignant insulinoma. Anticancer Res 16:1707–1717 Pavelic K, Hrascan R, Kapitanovic S et al. (1996) Molecular genetics of malignant insulinoma. Anticancer Res 16:1707–1717
27.
go back to reference Rheinwald JG, Hahn WC, Ramsey MR et al. (2002) A two-stage, p16INK4a- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 22:5157–5172CrossRefPubMed Rheinwald JG, Hahn WC, Ramsey MR et al. (2002) A two-stage, p16INK4a- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 22:5157–5172CrossRefPubMed
28.
go back to reference Fowler DL, Wood WG, Koontz PG Jr (1980) Endogenous hyperinsulinism. Am J Gastroenterol 74:321–327PubMed Fowler DL, Wood WG, Koontz PG Jr (1980) Endogenous hyperinsulinism. Am J Gastroenterol 74:321–327PubMed
29.
go back to reference Mettus RV, Rane SG (2003) Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice. Oncogene 22:8413–8421CrossRefPubMed Mettus RV, Rane SG (2003) Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice. Oncogene 22:8413–8421CrossRefPubMed
30.
go back to reference Miliani de Marval PL, Gimenez-Conti IB, LaCave M, Martinez LA, Conti CJ, Rodriguez-Puebla ML (2001) Transgenic expression of cyclin-dependent kinase 4 results in epidermal hyperplasia, hypertrophy, and severe dermal fibrosis. Am J Pathol 159:369–379PubMed Miliani de Marval PL, Gimenez-Conti IB, LaCave M, Martinez LA, Conti CJ, Rodriguez-Puebla ML (2001) Transgenic expression of cyclin-dependent kinase 4 results in epidermal hyperplasia, hypertrophy, and severe dermal fibrosis. Am J Pathol 159:369–379PubMed
31.
go back to reference Huang ZY, Baldwin RL, Hedrick NM, Gutmann DH (2002) Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo. Oncogene 21:1325–1334CrossRefPubMed Huang ZY, Baldwin RL, Hedrick NM, Gutmann DH (2002) Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo. Oncogene 21:1325–1334CrossRefPubMed
32.
go back to reference Miliani de Marval PL, Macias E, Conti CJ, Rodriguez-Puebla ML (2004) Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene 23:1863–1873CrossRefPubMed Miliani de Marval PL, Macias E, Conti CJ, Rodriguez-Puebla ML (2004) Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene 23:1863–1873CrossRefPubMed
33.
go back to reference Lazarov M, Kubo Y, Cai T et al. (2002) CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 8:1105–1114CrossRefPubMed Lazarov M, Kubo Y, Cai T et al. (2002) CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 8:1105–1114CrossRefPubMed
34.
go back to reference Ortega S, Malumbres M, Barbacid M (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602:73–87CrossRefPubMed Ortega S, Malumbres M, Barbacid M (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602:73–87CrossRefPubMed
35.
go back to reference Dor Y, Brown J, Martinez OI, Melton DA (2004) Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41–46CrossRefPubMed Dor Y, Brown J, Martinez OI, Melton DA (2004) Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41–46CrossRefPubMed
36.
go back to reference Bonner-Weir S (2000) Life and death of the pancreatic beta cells. Trends Endocrinol Metab 11:375–78CrossRef Bonner-Weir S (2000) Life and death of the pancreatic beta cells. Trends Endocrinol Metab 11:375–78CrossRef
37.
go back to reference Marzo N, Mora C, Fabregat ME et al. (2004) Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 diabetes. Diabetologia 47:686–694CrossRefPubMed Marzo N, Mora C, Fabregat ME et al. (2004) Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 diabetes. Diabetologia 47:686–694CrossRefPubMed
Metadata
Title
In vivo proliferation of differentiated pancreatic islet beta cells in transgenic mice expressing mutated cyclin-dependent kinase 4
Authors
S. Hino
T. Yamaoka
Y. Yamashita
T. Yamada
J. Hata
M. Itakura
Publication date
01-10-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1522-4

Other articles of this Issue 10/2004

Diabetologia 10/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.